Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

ViiV's Dovato: Treatment-Naive HIV Is Earmarked For The "Complete Regimen"

The first approval in the US of a once-daily single-tablet, two-drug regimen for treatment-naive HIV from the HIV/AIDS therapy specialist, ViiV Healthcare, suggests a shift away from three-drug regimens for HIV/AIDS could be gathering pace.

Approvals Infectious Diseases

'Pharma Fireworks': Pipeline Catalysts To Watch Out For In Q2

Scrip looks at some the key clinical and regulatory pharma events that will spark attention during the next three months, according to Biomedtracker's latest quarterly outlook report.

Clinical Trials Drug Review

GSK Forms New Commercial Trade Channel Team In India

GlaxoSmithKline India has carved out a specialized team with close to 300 personnel to engage with pharmacists. It is seeking to plug product availability gaps and address Rx switching at the retail level in the competitive and largely out-of-pocket Indian market.

Commercial Strategy

Biohaven Pays $105m For Turbo Boost In Migraine Drug Review Race

Biohaven has acquired a priority review voucher from GW Pharma to accelerate the US review of rimegepant, its oral CGRP receptor antagonist for migraine. The firm is competing with Allergan and Lilly in a race to get the next oral treatment approved.

Drug Review Neurology

Going Generic: Big Brands Poised To Lose Marketing Exclusivity In The US In 2019

With the first generic versions of blockbuster brands like Advair, Lyrica, Restasis and Sensipar and the first biosimilars of Herceptin, Avastin and Rituxan expected to launch in the US, 2019 could be a notable year for generics and biosimilars.
Generic Drugs Market Intelligence

Interview: Head Of Turkish Industry Body Highlights Key Challenges In 2019

Production localization and the fixed rate set for the euro against the lira will be key topics for the pharma industry in Turkey this year, with the expected further devaluation of the domestic currency likely to inflict more damage on companies. Turgut Tokgöz, secretary general of the Turkish industry association, spoke to Scrip.

Turkey Trade

From Stockpiling To Product Launches: Norgine Executive Shares Brexit Fears

A European firm with significant operations in the UK, Norgine has invested considerable resources in preparing for Brexit. With less than three weeks to go before the UK is scheduled to leave the EU, chief operating officer Peter Martin is very concerned about the risks of a no-deal Brexit, and the lack of clarity on what will happen next.

Brexit Trade

GW Pharma Looks Forward To EU Epidyolex Launch

Anticipating pan-EU approval of Epidyolex within the next six months, GW Pharmaceuticals is gearing up to launch what would be the first plant-derived cannabinoid medicine to be approved under the EU centralized procedure.

Companies Neurology

Scrip's Guide To Spinal Muscular Atrophy Therapies

INFOGRAPHIC: The prospects for patients with spinal muscular atrophy, the leading cause of genetic death in infants, have  been revolutionized by the arrival of the first approved drug for the disease, Biogen’s blockbuster Spinraza. Now, other firms with equally revolutionary product candidates are giving chase. Scrip takes a look at the main contenders.

Rare Diseases Research & Development
See All
Advertisement
UsernamePublicRestriction

Register